CYP2D6 gene test in psychiatric patients and healthy volunteers

Scandinavian Journal of Clinical and Laboratory Investigation
J O RasmussenK A Nielsen

Abstract

Antipsychotic drug therapy meets difficulties in predicting response in psychiatric patients. The medical treatment of these patients may be improved significantly by systematic phamacogenetic diagnosis identifying the drug metabolic capacities of each patient. Genetic polymorphisms in the coding sequence for the drug metabolizing cytochrome P450 enzyme CYP2D6 represent a pharmacogenetic target. A cohort (n = 225) representing psychiatric patients seen during an 18-month trial period was included in the project after the subjects accepted a blood sample being taken to analyse their CYP2D6 allelic composition. To investigate any putative difference in allele frequencies among the psychiatric patients compared to earlier publications on allele frequencies in Caucasian populations, another cohort (n = 122) of local healthy volunteers was likewise included. Allelic frequencies in the psychiatric patients and healthy volunteers were indistinguishable. Alleles *1 and *2 encoding for normal enzyme activity and alleles *3, *4, *5, *6, *13/*16 representing non-active forms were found as well as alleles *9, *10, *41 encoding for enzymes with decreased activity. Furthermore, examples of the previously described duplications of *1 and *2, ...Continue Reading

References

Dec 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·I JohanssonM Ingelman-Sundberg
Aug 1, 1996·Pharmacogenetics·I JohanssonM Ingelman-Sundberg
Feb 20, 2002·British Journal of Clinical Pharmacology·Leif BertilssonAyman Al-Shurbaji
Aug 2, 2002·Clinical Pharmacology and Therapeutics·Andrea GaedigkJ Steven Leeder
Aug 13, 2002·Pharmacogenetics·Thomas RauThomas Eschenhagen
Oct 19, 2002·Clinical Pharmacology and Therapeutics·Jürgen BrockmöllerIvar Roots
Oct 16, 2004·Journal of Medicinal Chemistry·Carol A KempMichael J Sutcliffe
Nov 24, 2004·Drug Metabolism Reviews·Ivar RootsAlfred G Hildebrandt
Dec 8, 2004·Current Topics in Medicinal Chemistry·Ann K Daly
Dec 31, 2004·International Journal of Clinical Pharmacology and Therapeutics·H M JamesA A Somogyi
Jan 27, 2005·The Journal of Clinical Psychiatry·Jose de LeonPeter J Wedlund

❮ Previous
Next ❯

Citations

Sep 21, 2007·Current Psychiatry Reports·Charles U Nnadi, Anil K Malhotra
Feb 26, 2010·Journal of Toxicology and Environmental Health. Part B, Critical Reviews·Patricia NeafseyBabasaheb Sonawane
Apr 19, 2007·Clinical Chemistry and Laboratory Medicine : CCLM·John W J HinrichsJan van der Weide
Apr 22, 2008·Human Psychopharmacology·Ana Fernández-SantanderFélix Gómez-Gallego
Nov 5, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Louise HerbildDorte Gyrd-Hansen
Jan 26, 2008·International Journal of Technology Assessment in Health Care·Louise HerbildMickael Bech
Jan 25, 2011·Scandinavian Journal of Public Health·Louise HerbildKirsten Annette Nielsen
Jul 20, 2007·Fundamental & Clinical Pharmacology·Kostas ArvanitidisVangelis G Manolopoulos
Apr 12, 2008·European Archives of Psychiatry and Clinical Neuroscience·Ramón Cacabelos
Dec 15, 2007·Molecular Diagnosis & Therapy·Ramón Cacabelos
Apr 25, 2007·Scandinavian Journal of Clinical and Laboratory Investigation·K A NielsenS Gille
Feb 13, 2016·Journal of Child and Adolescent Psychopharmacology·Ian R McGrane, Joshua G Loveland
Feb 26, 2021·Translational Psychiatry·Anne B KoopmansPeter N van Harten

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here